<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39388388</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>10</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>12</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>10</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Risk of systemic lupus erythematosus flare after COVID-19 hospitalization: A matched cohort study.</ArticleTitle><Pagination><StartPage>e0309316</StartPage><MedlinePgn>e0309316</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0309316</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0309316</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To analyze the risk of systemic lupus erythematosus (SLE) flare after admission for COVID-19.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We performed a matched cohort study using the Assistance Publique-Hôpitaux de Paris Clinical Data Warehouse which collects structured medical, biological and administrative information from 11 million patients in Paris area, France. Each SLE patient hospitalized with a COVID-19 diagnosis code between March 2020 and December 2021 was matched to one SLE control patient with an exact matching procedure using age ±3 years, gender, chronic kidney disease, end-stage renal disease, and serological activity. The main outcome was a lupus flare during the 6 months follow-up. A flare was considered if a) documented by the treating physician in the patient's EHR and b) justifying a change in SLE treatment. The electronic health records (EHRs) were individually checked for data accuracy.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 4,533 SLE patients retrieved from the database, 81 (2.8%) have been admitted for COVID-19 between March 2020 and December 31, 2021, and 79 (n = 79/81,97.5%) were matched to a unique unexposed SLE. During follow-up, a flare occurred in 14 (17.7%) patients from the COVID-19 group as compared to 5 (6.3%) in the unexposed control group, including 4 lupus nephritis in the exposed group and 1 in the control group. After adjusting for HCQ use at index date and history of lupus nephritis, the risk of flare was higher in exposed SLE patients (hazard ratio [95% confidence interval] of 3.79 [1.49-9.65]).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">COVID-19 hospitalization is associated with an increased risk of flare in SLE.</AbstractText><CopyrightInformation>Copyright: © 2024 Mageau et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mageau</LastName><ForeName>Arthur</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2995-767X</Identifier><AffiliationInfo><Affiliation>IAME, UMR 1137 INSERM, Team Descid Université Paris Cité and Université Sorbonne Paris Nord, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Département de médecine interne, Hôpital Bichat-Claude Bernard, Assistance Publique- Hôpitaux de Paris, Université Paris Cité, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CRI, UMR 1149 INSERM, ERL 8252 CNRS, LabEx Inflamex, Université Paris Cité, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Géradin</LastName><ForeName>Christel</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Département de médecine interne, Hôpital Bichat-Claude Bernard, Assistance Publique- Hôpitaux de Paris, Université Paris Cité, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sorbonne Université, Inserm, Institut Pierre-Louis d'Epidémiologie et de Santé Publique, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sallah</LastName><ForeName>Kankoé</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>INSERM CIC-EC 1425, Hôpital Bichat Claude Bernard, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Research, Biostatistics and Epidemiology Department, AP-HP Nord-Université Paris, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papo</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Département de médecine interne, Hôpital Bichat-Claude Bernard, Assistance Publique- Hôpitaux de Paris, Université Paris Cité, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CRI, UMR 1149 INSERM, ERL 8252 CNRS, LabEx Inflamex, Université Paris Cité, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sacre</LastName><ForeName>Karim</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-6544-234X</Identifier><AffiliationInfo><Affiliation>Département de médecine interne, Hôpital Bichat-Claude Bernard, Assistance Publique- Hôpitaux de Paris, Université Paris Cité, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CRI, UMR 1149 INSERM, ERL 8252 CNRS, LabEx Inflamex, Université Paris Cité, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Timsit</LastName><ForeName>Jean-François</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>IAME, UMR 1137 INSERM, Team Descid Université Paris Cité and Université Sorbonne Paris Nord, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Département de Réanimation Médicale et Infectieuse, Assistance Publique- Hôpitaux de Paris, Université Paris Cité, Hôpital Bichat-Claude-Bernard, Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="Y">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>22</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>22</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>10</Day><Hour>13</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39388388</ArticleId><ArticleId IdType="pmc">PMC11466388</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0309316</ArticleId><ArticleId IdType="pii">PONE-D-23-32994</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Crow MK. Type I interferon in the pathogenesis of lupus. J Immunol Baltim Md 1950. 2014;192: 5459–5468. doi: 10.4049/jimmunol.1002795</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1002795</ArticleId><ArticleId IdType="pmc">PMC4083591</ArticleId><ArticleId IdType="pubmed">24907379</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta S, Tatouli IP, Rosen LB, Hasni S, Alevizos I, Manna ZG, et al.. Distinct Functions of Anti-interferon Autoantibodies in Systemic Lupus Erythematosus: A Comprehensive Analysis of Anticytokine Autoantibodies in Common Rheumatologic Diseases. Arthritis Rheumatol Hoboken NJ. 2016;68: 1677–1687. doi: 10.1002/art.39607</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39607</ArticleId><ArticleId IdType="pmc">PMC5391258</ArticleId><ArticleId IdType="pubmed">26815287</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann H-H, Zhang Y, et al.. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370. doi: 10.1126/science.abd4585</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd4585</ArticleId><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, et al.. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370. doi: 10.1126/science.abd4570</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd4570</ArticleId><ArticleId IdType="pmc">PMC7857407</ArticleId><ArticleId IdType="pubmed">32972995</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathian A, Breillat P, Dorgham K, Bastard P, Charre C, Lhote R, et al.. Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-α. Ann Rheum Dis. 2022;81: 1695–1703. doi: 10.1136/ard-2022-222549</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard-2022-222549</ArticleId><ArticleId IdType="pubmed">35973806</ArticleId></ArticleIdList></Reference><Reference><Citation>Mageau A, Nicaise Roland P, Goulenok T, Farkh C, Charles N, Sacre K. Systemic lupus erythematosus flare following SARS-CoV2 infection: the implication of IFNα and anti-IFNα autoantibodies. Clin Exp Rheumatol. 2022;40: 1450. doi: 10.55563/clinexprheumatol/5pubx8</Citation><ArticleIdList><ArticleId IdType="doi">10.55563/clinexprheumatol/5pubx8</ArticleId><ArticleId IdType="pubmed">35238761</ArticleId></ArticleIdList></Reference><Reference><Citation>Mageau A, Papo T, Ruckly S, Strukov A, van Gysel D, Sacre K, et al.. Survival after COVID-19-associated organ failure among inpatients with systemic lupus erythematosus in France: a nationwide study. Ann Rheum Dis. 2022;81: 569–574. doi: 10.1136/annrheumdis-2021-221599</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221599</ArticleId><ArticleId IdType="pubmed">34893471</ArticleId></ArticleIdList></Reference><Reference><Citation>Mageau A, Aldebert G, Gysel DV, Papo T, Timsit J-F, Sacre K. SARS-CoV-2 infection among inpatients with systemic lupus erythematosus in France: a nationwide epidemiological study. Ann Rheum Dis. 2021. [cited 5 May 2021]. doi: 10.1136/annrheumdis-2021-220010</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-220010</ArticleId><ArticleId IdType="pubmed">33727216</ArticleId></ArticleIdList></Reference><Reference><Citation>Alharthy A, Faqihi F, Nasim N, Noor A, Akhtar S, Balshi A, et al.. COVID-19 in a patient with a flare of systemic lupus erythematosus: A rare case-report. Respir Med Case Rep. 2020;31: 101252. doi: 10.1016/j.rmcr.2020.101252</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmcr.2020.101252</ArticleId><ArticleId IdType="pmc">PMC7557168</ArticleId><ArticleId IdType="pubmed">33078093</ArticleId></ArticleIdList></Reference><Reference><Citation>Naranjo-Millán JA, Bedoya-Joaqui V, Cañas CA. Systemic lupus erythematosus flare during SARS-CoV-2 infection: Report of 3 cases presented during the fourth wave of the pandemic in Colombia. Int J Rheum Dis. 2023. doi: 10.1111/1756-185X.14657</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1756-185X.14657</ArticleId><ArticleId IdType="pubmed">36880687</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasser N, Kurban M, Abbas O. Plasmacytoid dendritic cells and type I interferons in flares of systemic lupus erythematosus triggered by COVID-19. Rheumatol Int. 2021;41: 1019–1020. doi: 10.1007/s00296-021-04825-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-021-04825-3</ArticleId><ArticleId IdType="pmc">PMC7933913</ArticleId><ArticleId IdType="pubmed">33666725</ArticleId></ArticleIdList></Reference><Reference><Citation>ATIH. International Classification of Disease, 10th revision. Official reference document defining the coding used in the APHP data warehouse database. 2023. https://sante.gouv.fr/fichiers/bos/2022/2022.9bis.BOS.pdf</Citation></Reference><Reference><Citation>ATIH. Classification commune des actes médicaux (CCAM). Official document defining the codes used in the APHP clinical data warehouse. 2023. https://www.atih.sante.fr/sites/default/files/public/content/4441/ccam_descriptive_a_usage_pmsi_2023_version_provisoire.pdf</Citation></Reference><Reference><Citation>Aringer M, Costenbader KH, Daikh DI, Brinks R, Mosca M, Ramsey-Goldman R, et al.. 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol Hoboken NJ. 2019;71: 1400–1412. doi: 10.1002/art.40930</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40930</ArticleId><ArticleId IdType="pmc">PMC6827566</ArticleId><ArticleId IdType="pubmed">31385462</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin DY, Wei LJ. The Robust Inference for the Cox Proportional Hazards Model. J Am Stat Assoc. 1989;84: 1074–1078. doi: 10.1080/01621459.1989.10478874</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01621459.1989.10478874</ArticleId></ArticleIdList></Reference><Reference><Citation>Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk. J Am Stat Assoc. 1999;94: 496–509. doi: 10.2307/2670170</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2670170</ArticleId></ArticleIdList></Reference><Reference><Citation>Weening JJ, D’agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al.. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65: 521–530. doi: 10.1111/j.1523-1755.2004.00443.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1523-1755.2004.00443.x</ArticleId><ArticleId IdType="pubmed">14717922</ArticleId></ArticleIdList></Reference><Reference><Citation>Gartshteyn Y, Askanase AD, Schmidt NM, Bernstein EJ, Khalili L, Drolet R, et al.. COVID-19 and systemic lupus erythematosus: a case series. Lancet Rheumatol. 2020;2: e452–e454. doi: 10.1016/S2665-9913(20)30161-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(20)30161-2</ArticleId><ArticleId IdType="pmc">PMC7250558</ArticleId><ArticleId IdType="pubmed">32835249</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamani B, Moeini Taba S-M, Shayestehpour M. Systemic lupus erythematosus manifestation following COVID-19: a case report. J Med Case Reports. 2021;15: 29. doi: 10.1186/s13256-020-02582-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13256-020-02582-8</ArticleId><ArticleId IdType="pmc">PMC7832415</ArticleId><ArticleId IdType="pubmed">33494816</ArticleId></ArticleIdList></Reference><Reference><Citation>Joo YB, Kim K-J, Park K-S, Park Y-J. Influenza infection as a trigger for systemic lupus erythematosus flares resulting in hospitalization. Sci Rep. 2021;11: 4630. doi: 10.1038/s41598-021-84153-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-84153-5</ArticleId><ArticleId IdType="pmc">PMC7907068</ArticleId><ArticleId IdType="pubmed">33633288</ArticleId></ArticleIdList></Reference><Reference><Citation>James JA, Neas BR, Moser KL, Hall T, Bruner GR, Sestak AL, et al.. Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum. 2001;44: 1122–1126. doi: 10.1002/1529-0131(200105)44:5&amp;lt;1122::AID-ANR193&amp;gt;3.0.CO;2-D</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1529-0131(200105)44:5&amp;lt;1122::AID-ANR193&amp;gt;3.0.CO;2-D</ArticleId><ArticleId IdType="pubmed">11352244</ArticleId></ArticleIdList></Reference><Reference><Citation>Quaglia M, Merlotti G, De Andrea M, Borgogna C, Cantaluppi V. Viral Infections and Systemic Lupus Erythematosus: New Players in an Old Story. Viruses. 2021;13: 277. doi: 10.3390/v13020277</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13020277</ArticleId><ArticleId IdType="pmc">PMC7916951</ArticleId><ArticleId IdType="pubmed">33670195</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff MC, Ramonell RP, Nguyen DC, Cashman KS, Saini AS, Haddad NS, et al.. Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. Nat Immunol. 2020;21: 1506–1516. doi: 10.1038/s41590-020-00814-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-00814-z</ArticleId><ArticleId IdType="pmc">PMC7739702</ArticleId><ArticleId IdType="pubmed">33028979</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenks SA, Cashman KS, Zumaquero E, Marigorta UM, Patel AV, Wang X, et al.. Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus Erythematosus. Immunity. 2018;49: 725–739.e6. doi: 10.1016/j.immuni.2018.08.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2018.08.015</ArticleId><ArticleId IdType="pmc">PMC6217820</ArticleId><ArticleId IdType="pubmed">30314758</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxena A, Engel AJ, Banbury B, Hasan G, Fraser N, Zaminski D, et al.. Breakthrough SARS-CoV-2 infections, morbidity, and seroreactivity following initial COVID-19 vaccination series and additional dose in patients with SLE in New York City. Lancet Rheumatol. 2022;4: e582–e585. doi: 10.1016/S2665-9913(22)00190-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(22)00190-4</ArticleId><ArticleId IdType="pmc">PMC9275793</ArticleId><ArticleId IdType="pubmed">35856060</ArticleId></ArticleIdList></Reference><Reference><Citation>Mageau A, Ferré VM, Goulenok T, Charpentier C, Delory N, Francois C, et al.. Severely impaired humoral response against SARS-CoV-2 variants of concern following two doses of BNT162b2 vaccine in patients with systemic lupus erythematosus (SLE). Ann Rheum Dis. 2022; annrheumdis-2022-222498. doi: 10.1136/annrheumdis-2022-222498</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2022-222498</ArticleId><ArticleId IdType="pubmed">35396228</ArticleId></ArticleIdList></Reference><Reference><Citation>Mageau A, Tchen J, Ferré VM, Nicaise-Roland P, Descamps D, Delory N, et al.. Impact of BNT162b2 mRNA anti-SARS-CoV-2 vaccine on interferon-alpha production by plasmacytoid dendritic cells and autoreactive T cells in patients with systemic lupus erythematosus: The COVALUS project. J Autoimmun. 2023;134: 102987. doi: 10.1016/j.jaut.2022.102987</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2022.102987</ArticleId><ArticleId IdType="pmc">PMC9760608</ArticleId><ArticleId IdType="pubmed">36563528</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>